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Abstract: The primary goal of this paper is to predict fasting glucose levels in type 2 diabetes
(T2D) in long-acting insulin treatment. The paper presents a model for simulating insulin-
glucose dynamics in T2D patients. The model combines a physiological model of type 1 diabetes
(T1D) and an endogenous insulin production model in T2D. We include a review of sources of
variance in fasting glucose values in long-acting insulin treatment, with respect to dose guidance
algorithms. We use the model to simulate fasting glucose levels in T2D long-acting insulin
treatment and compare the results with clinical trial results where a dose guidance algorithm
was used. We investigate sources of variance and through simulations evaluate the contribution
of adherence to variance and dose guidance quality. The results suggest that the model for
simulation of T2D patients is sufficient for simulating fasting glucose levels during titration in
a clinical trial. Adherence to insulin injections plays an important role considering variance in
fasting glucose. For adherence levels 100%, 70% and 50%, the coefficient of variation of simulated
fasting glucose levels were similar to observed variances in insulin treatment. The dose guidance
algorithm suggested too large doses in 0.0%, 5.3% and 24.4% of cases, respectively. Adherence
to treatment is an important source of variance in long-acting insulin titration.
Keywords: Biomedical systems, Diabetes, Physiological models, Medical applications, Type 2
Diabetes.
1. INTRODUCTION
Patients with type 2 diabetes (T2D) initiating insulin
treatment typically inject long-acting insulin once daily to
lower fasting glucose (FG) concentration. To determine the
individual patients optimal daily dose, patients increase
doses based on self-monitored blood glucose (SMBG), until
the desired FG level is reached. This process is called
titration, and is a delicate procedure. The effect of too
little doses of insulin is hyperglycemia. Untreated hyper-
glycemia can cause long term complications which include
cardiovascular disease, neuropathy, kidney damage and
other complications. Too high doses of insulin can lead
to hypoglycemia. In mild cases, hypoglycemia will cause
confusion and seizures. In severe cases it may cause coma
or death. The main challenges in insulin titration include
complexity of regimen and dose calculations, fear of hypo-
glycemia, the need for frequent SMBG measurements and
lack of confidence (Arnolds et al., 2013). This leads to too
seldom dose adjustments and titration can take years if
successful at all (Bashan et al., 2011).
1 This project is funded by Innovation Fund Denmark through
the Industrial PhD project 5189-00033B, and the Danish Diabetes
Academy supported by the Novo Nordisk Foundation
To address the need for titration assistance, a number
of research and industrial groups have developed auto-
matic algorithms for dose guidance (Bergenstal et al.,
2012; Cook et al., 2005; Bajaj et al., 2016). SMBG mea-
surements have been demonstrated to be sufficient to
adjust insulin dosage, provided that insulin adjustments
are modest (Bergenstal et al., 2012). However, variance
in SMBG not only stems from device accuracy but also
biological and drug-related day-to-day variance, measuring
technique and lifestyle changes. If the measured FG levels
are high, the algorithms recommend an increase in insulin
dose by a certain amount. Similarly, if the FG is low, the
dose is decreased. The algorithms assume that the input,
i.e. FG levels, is correlated with the response to the output,
i.e. recommended dose. We therefore hypothesize that
current titration algorithms are suboptimal with respect
to high variance in glucose levels.
The motivation of this paper is to present an overview
of the sources of variance in FG levels during insulin
initiation and intensification, and to create a simulation
model for use in development of safe and effective titration
algorithms, and to evaluate the contribution of adherence
in FG variance.
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fasting glucose. For adherence levels 100%, 70% and 50%, the coefficient of variation of simulated
fasting glucose levels were similar to observed variances in insulin treatment. The dose guidance
algorithm suggested too large doses in 0.0%, 5.3% and 24.4% of cases, respectively. Adherence
to treatment is an important source of variance in long-acting insulin titration.
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1. INTRODUCTION
Patients with type 2 diabetes (T2D) initiating insulin
treatment typically inject long-acting insulin once daily to
lower fasting glucose (FG) concentration. To determine the
individual patients optimal daily dose, patients increase
doses based on self-monitored blood glucose (SMBG), until
the desired FG level is reached. This process is called
titration, and is a delicate procedure. The effect of too
little doses of insulin is hyperglycemia. Untreated hyper-
glycemia can cause long term complications which include
cardiovascular disease, neuropathy, kidney damage and
other complications. Too high doses of insulin can lead
to hypoglycemia. In mild cases, hypoglycemia will cause
confusion and seizures. In severe cases it may cause coma
or death. The main challenges in insulin titration include
complexity of regimen and dose calculations, fear of hypo-
glycemia, the need for frequent SMBG measurements and
lack of confidence (Arnolds et al., 2013). This leads to too
seldom dose adjustments and titration can take years if
successful at all (Bashan et al., 2011).
1 This project is funded by Innovation Fund Denmark through
the Industrial PhD project 5189-00033B, and the Danish Diabetes
Academy supported by the Novo Nordisk Foundation
To address the need for titration assistance, a number
of research and industrial groups have developed auto-
matic algorithms for dose guidance (Bergenstal et al.,
2012; Cook et al., 2005; Bajaj et al., 2016). SMBG mea-
surements have been demonstrated to be sufficient to
adjust insulin dosage, provided that insulin adjustments
are modest (Bergenstal et al., 2012). However, variance
in SMBG not only stems from device accuracy but also
biological and drug-related day-to-day variance, measuring
technique and lifestyle changes. If the measured FG levels
are high, the algorithms recommend an increase in insulin
dose by a certain amount. Similarly, if the FG is low, the
dose is decreased. The algorithms assume that the input,
i.e. FG levels, is correlated with the response to the output,
i.e. recommended dose. We therefore hypothesize that
current titration algorithms are suboptimal with respect
to high variance in glucose levels.
The motivation of this paper is to present an overview
of the sources of variance in FG levels during insulin
initiation and intensification, and to create a simulation
model for use in development of safe and effective titration
algorithms, and to evaluate the contribution of adherence
in FG variance.
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1. INTRODUCTION
Patients with type 2 diabetes (T2D) initiating insulin
treatment typically inject long-acting insulin once daily to
lower fasting glucose (FG) concentration. To determine the
individual patients optimal daily dose, patients increase
doses based on self-monitored blood glucose (SMBG), until
the desired FG level is reached. This process is called
titration, and is a delicate procedure. The effect of too
little doses of insulin is hyperglycemia. Untreated hyper-
glycemia can cause long term complications which include
cardiovascular disease, neuropathy, kidney damage and
other complications. Too high doses of insulin can lead
to hypoglycemia. In mild cases, hypoglycemia will cause
confusion and seizures. In severe cases it may cause coma
or death. The main challenges in insulin titration include
complexity of regimen and dose calculations, fear of hypo-
glycemia, the need for frequent SMBG measurements and
lack of confidence (Arnolds et al., 2013). This leads to too
seldom dose adjustments and titration can take years if
successful at all (Bashan et al., 2011).
1 This project is funded by Innovation Fund Denmark through
the Industrial PhD project 5189-00033B, and the Danish Diabetes
Academy supported by the Novo Nordisk Foundation
To address the need for titration assistance, a number
of research and industrial groups have developed auto-
matic algorithms for dose guidance (Bergenstal et al.,
2012; Cook et al., 2005; Bajaj et al., 2016). SMBG mea-
surements have been demonstrated to be sufficient to
adjust insulin dosage, provided that insulin adjustments
are modest (Bergenstal et al., 2012). However, variance
in SMBG not only stems from device accuracy but also
biological and drug-related day-to-day variance, measuring
technique and lifestyle changes. If the measured FG levels
are high, the algorithms reco mend an increase in insulin
dose by a certain amount. Similarly, if the FG is low, the
dose is decreased. The algorithms assume that the input,
i.e. FG levels, is correlated with the response to the output,
i.e. recommended dose. We therefore hypothesize that
current titration algorithms are suboptimal with respect
to high variance in glucose levels.
The motivation of this paper is to present an overview
of the sources of variance in FG levels during insulin
initiation and intensification, and to create a simulation
model for use in development of safe and effective titration
algorithms, and to evaluate the contribution of adherence
in FG variance.
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In this paper, Section 2 presents a review and suggested
categorization of variances in long-acting insulin titration
for T2D patients. In Section 3 we suggest a model of
glucose-insulin dynamics to generate a cohort of T2D pa-
tients initiating long-acting insulin treatment. In Section 4
we present the results of comparing simulation results with
a clinical trial. We also evaluate the effect of adherence
on safety in dose guidance. Section 5 presents a short
conclusion of the methods and results.
2. SOURCES OF VARIANCE
A key challenge in adaptive glucose control is to determine
dose sizes based on data with large day-to-day variability.
Variability is caused by different factors, and some are
easier to mitigate than others. Lifestyle and physiological
state are closely related, and the sources of variance are
therefore difficult to completely separate. Kildegaard et al.
(2009) divided sources of variance in T1D into five cat-
egories; metabolic, insulin, glucose monitoring and meal
variability, and lifestyle and compliance. Here we divide
sources into three categories, each discussed in the follow-
ing subsections; 1) metabolic variability including insulin
variability, 2) variations due to lifestyle and adherence and
3) device related variability.
2.1 Metabolic variability
Glucose metabolism depends on the physiological state of
the body. Stress causes the release of a number of hor-
mones that elevate glucose levels, while exercise and weight
loss increase insulin sensitivity (Guthrie and Guthrie,
2009).
Non-insulin related variability
Research groups have previously investigated day-to-day
and intraday glucose variability in patients with T2D.
In a study by Ollerton et al. (1999), day-to-day FG
variability in newly diagnosed T2D patients not receiving
diabetes medication was approximately 14%. They also
found that high levels of FG are correlated with higher
glucose variance.
Studies on healthy humans have suggested that daily
fluctuations in insulin sensitivity contribute to variations
in glucose uptake. For instance, Gibson and Jarrett (1972)
found that fall in blood sugar following doses of 0.05-0.1
IU/kg was significantly less for normal weight humans in
the afternoon than in the morning. The observed difference
was around 0.5-1.0 mmol/L. For obese individuals, their
results suggested that this difference decreased with higher
weight.
Insulin related variability
Basal insulin preparations act in different ways, and have
different pharmacokinetic (PK) and pharmacodynamic
(PD) characteristics. Some long acting insulin types crys-
tallize subcutaneously (SC) after injection, and slowly dis-
solve to enter the blood stream. These insulins are prone to
high day-to-day PK/PD variability due to great variability
in the break-down process. Newer insulins allow less vari-
ability by forming soluble chains in the skin, which then
slowly release insulin into the circulation, (Heise et al.,
2012). Fig. 1 illustrates day-to-day coefficient of variation
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Fig. 1. Day-to-day CV in pharmacodynamics of degludec,
detemir and glargine. GIR AUC and GIR max are glu-
cose infusion rate area under the curve and maximum
value (Heise et al., 2012; Klein et al., 2007).
(CV) in PD for T1D and T2D, for a number of long acting
insulins on the market. For glargine, the CV is around
150% for maximum glucose infusion rate (GIR), while for
detemir it is reduced to around 40%. The variations in
T2D are greater than in T1D for detemir and glargine,
but no data is available for degludec in T2D.
One source of variation during insulin treatment initiation
is the dawn phenomenon. Extensive studies have shown
that it is a frequent event across the population of T2D pa-
tients on oral treatment (Monnier et al., 2013). In a clinical
trial with T2D patients on metformin only, glucose levels
were monitored overnight while initiating and intensifying
insulin treatment. The results showed that in non-insulin
treated patients, FG levels increased overnight by approx-
imately 20 mg/dl over 4-5 hours. However, after 6 months
of insulin treatment intensification the phenomenon was
eliminated (Monnier et al., 2013). Therefore its effect are
only apparent early in the treatment. Degludec is ultra-
long acting insulin with a half-life of over 25 hours. The
long half-life causes the drug to reach steady state after
2-3 days, (Heise et al., 2015). This means that there is
day-to-day variance in the FG measurements following
a dose size change, and the full response to a new dose
size is reached in 2-3 days. The overlap decreases random
variation which, theoretically, results in a more stable
treatment. Additionally, forgetting a dose is less critical
than with previous drugs due to the long overlap from the
previous injections (Haahr and Heise, 2014).
2.2 Lifestyle and adherence
Basal insulin treatment is complex and requires extensive
work from the patient. For many patients, this is a disrup-
tion of life prior to diagnosis, where they are required to
manage dose calculations and daily do SMBG and injec-
tions. A study that investigated variance in glucose levels
of T2D subjects on stable basal insulin doses, observed a
total CV in FG of 35%. The results indicated that factors
including consumption of sugars and adherence to treat-
ment were highly correlated with FG variance, explaining
21% of the CV, (Murata et al., 2004). Furthermore, insulin
sensitivity is correlated with level of activity, stress and
illness, and thereby glucose levels.
Adherence
Adherence to treatment is essential to successful glycemic
control and collecting reliable data on the level of adher-
ence is difficult (Cramer and Pugh, 2005).
Proceedings of the 20th IFAC World Congress
Toulouse, France, July 9-14, 2017
15652
15088 Tinna B. Aradóttir  et al. / IFAC PapersOnLine 50-1 (2017) 15086–15091
0
10
20
30
40
50
60
70
80
90
100
Peyrot et al. Cramer et al. Lee et al.
Syringe
Lee et al.     Pen
A
dh
er
en
ce
 (
%
) 
Peyrot et al.
Cramer et al.Pharmacy nd prescription 
based 
Survey b sed 
Fig. 2. Adherence measured as percentage of doses taken
compared to regimen (Cramer and Pugh, 2005; Lee
et al., 2006; Peyrot et al., 2012).
In a study by Peyrot et al. (2012) based on an Inter-
net survey of physicians and diabetes patients, around
30% of patients reported insulin omission 3.3 days in
the last month, and around 75% of physicians reported
that their patients on average omitted basal insulin 4.3
days per month. A total rate of omission was estimated
to be 3.1 days, which corresponds to approximately 90%
adherence to once-daily insulin treatment. Another study
used pharmacy databases and prescription data and found
that insulin use was 77% of the prescribed amount. They
furthermore found that significant predictors for adher-
ence included HbA1c levels, race and treatment intensity
(Cramer and Pugh, 2005). Another study on adherence
based on pharmacy and clinic databases found that ad-
herence was 62-69% based on injection device (Lee et al.,
2006). Fig. 2 illustrates a summary of results from three
studies using different methods to measure adherence.
Lifestyle
Physical activity increases insulin sensitivity. In a study
where insulin sensitivity and level of physical activity in
untreated T2D patients was investigated, insulin sensi-
tivity was 8% and 25% higher for those who did some
moderate and vigorous exercise than sedentary patients,
respectively, (Balkau et al., 2008). This is in line with a
review of studies on people with T2D, where changes in
insulin sensitivity were found to be 23% - 35% after 2
weeks of aerobic training. However, the determining factor
of insulin sensitivity is the total daily activity rather than
time spent sedentary or doing intensive exercise (Mann
et al., 2014).
In a study of FG in T2D patients on stable basal in-
sulin doses, the relationship between variance and meal
habits was investigated. No difference in CV was observed
between subjects with and without regular mealtimes,
or those who sometimes missed meals. CV was however
greater in those who consumed more sugars (Murata et al.,
2004).
2.3 Device related variability
Standards for accuracy of injection and measurement
devices exist (ISO 11608-1:2014, ISO 15197:2013). These
standards have tight ranges of accuracy, and need to be
reported fulfilled before the devices go to market. However,
when in the hands of health care professionals or patients
in daily settings, the quality of measurements is different
from what is reported in the lab.
Glucose monitoring
Kjome et al. (2010) compared the ISO 15197:2003 with
the difference in pharmacy and patient blood glucose
measurements. The limits recommended in the standard
from 2003 were ±20% for glucose levels equal or over
4.2 mmol/L and ±0.83 mmol/L for lower values. They
found that 5% of patients’ measurements deviated by more
than the recommended 20% from the pharmacy’s measure-
ments. They furthermore observed failure to comply with
performance guidelines for 50% of the patients. The user
errors included failure to clean hands, sampling technique,
validity of sampling strips and amount of blood used.
Kildegaard et al. (2009) listed a number of similar studies,
for SMBG monitors and continuous glucose monitoring
(CGM) devices. They found that the percentage of mea-
surements falling outside the ISO standard for the different
monitoring devices varied from under 5% up to around
30%, and CGM measurements showed higher errors. It
should be mentioned that even though CGM measure-
ments had larger errors, they provide useful insights into
glycemic trends and variations (Kildegaard et al., 2009).
Insulin pens
Accuracy of insulin pens as a source of variance is discussed
in e.g. Kildegaard et al. (2009). Insulin pens have shown
to have a CV of approximately 2%, when giving a dose
of 5U. At large doses, the CV is close to or less than
1%. Heise et al. (2014) studied the impact of volume and
speed of subcutaneous injections on perceived pain. They
found that backflow after injection was less than 1% CV.
Combined with the dosing accuracy of insulin pens, this
amount of variance is not likely to be clinically relevant.
3. SIMULATING A COHORT OF T2D PATIENTS
We use the Medtronic Virtual Patient (MVP) model de-
veloped by Kanderian et al. (2009) and a meal subsystem
described by Hovorka et al. (2004) to simulate a population
of virtual T1D patients, and augment this model with an
endogenous insulin production compartment to simulate
T2D (Ruan et al., 2015). We introduce a method for
simulating injections of long-acting insulin in a simulation
model intended for pump simulations. The ambition of this
model is to represent FG levels in T2D long-acting insulin
treatment.
3.1 Type 1 diabetes model
We use two meal compartments, D1 [mmol] and D2
[mmol], equivalent to what is described by Hovorka et al.
(2004), to describe orally ingested carbohydrates,
dD1(t)
dt
= D(t)− D1(t)
τm
, (1a)
dD2(t)
dt
=
D1(t)
τm
− D2(t)
τm
. (1b)
τm [min] is the peak time of absorption. D(t) [mmol/min]
is the amount of ingested carbohydrates per minute.
Given the amount of orally ingested carbohydrates d(t)
[mg/min], D(t) = AG
d(t)
MwG where MwG = 180.1559
[g/mol] is molar weight of glucose and AG is the unit
less CHO bioavailability. We assume 100% bioavailability,
AG = 1.
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Fig. 2. Adherence measured as percentage of doses taken
compared to regimen (Cramer and Pugh, 2005; Lee
et al., 2006; Peyrot et al., 2012).
In a study by Peyrot et al. (2012) based on an Inter-
net survey of physicians and diabetes patients, around
30% of patients reported insulin omission 3.3 days in
the last month, and around 75% of physicians reported
that their patients on average omitted basal insulin 4.3
days per month. A total rate of omission was estimated
to be 3.1 days, which corresponds to approximately 90%
adherence to once-daily insulin treatment. Another study
used pharmacy databases and prescription data and found
that insulin use was 77% of the prescribed amount. They
furthermore found that significant predictors for adher-
ence included HbA1c levels, race and treatment intensity
(Cramer and Pugh, 2005). Another study on adherence
based on pharmacy and clinic databases found that ad-
herence was 62-69% based on injection device (Lee et al.,
2006). Fig. 2 illustrates a summary of results from three
studies using different methods to measure adherence.
Lifestyle
Physical activity increases insulin sensitivity. In a study
where insulin sensitivity and level of physical activity in
untreated T2D patients was investigated, insulin sensi-
tivity was 8% and 25% higher for those who did some
moderate and vigorous exercise than sedentary patients,
respectively, (Balkau et al., 2008). This is in line with a
review of studies on people with T2D, where changes in
insulin sensitivity were found to be 23% - 35% after 2
weeks of aerobic training. However, the determining factor
of insulin sensitivity is the total daily activity rather than
time spent sedentary or doing intensive exercise (Mann
et al., 2014).
In a study of FG in T2D patients on stable basal in-
sulin doses, the relationship between variance and meal
habits was investigated. No difference in CV was observed
between subjects with and without regular mealtimes,
or those who sometimes missed meals. CV was however
greater in those who consumed more sugars (Murata et al.,
2004).
2.3 Device related variability
Standards for accuracy of injection and measurement
devices exist (ISO 11608-1:2014, ISO 15197:2013). These
standards have tight ranges of accuracy, and need to be
reported fulfilled before the devices go to market. However,
when in the hands of health care professionals or patients
in daily settings, the quality of measurements is different
from what is reported in the lab.
Glucose monitoring
Kjome et al. (2010) compared the ISO 15197:2003 with
the difference in pharmacy and patient blood glucose
measurements. The limits recommended in the standard
from 2003 were ±20% for glucose levels equal or over
4.2 mmol/L and ±0.83 mmol/L for lower values. They
found that 5% of patients’ measurements deviated by more
than the recommended 20% from the pharmacy’s measure-
ments. They furthermore observed failure to comply with
performance guidelines for 50% of the patients. The user
errors included failure to clean hands, sampling technique,
validity of sampling strips and amount of blood used.
Kildegaard et al. (2009) listed a number of similar studies,
for SMBG monitors and continuous glucose monitoring
(CGM) devices. They found that the percentage of mea-
surements falling outside the ISO standard for the different
monitoring devices varied from under 5% up to around
30%, and CGM measurements showed higher errors. It
should be mentioned that even though CGM measure-
ments had larger errors, they provide useful insights into
glycemic trends and variations (Kildegaard et al., 2009).
Insulin pens
Accuracy of insulin pens as a source of variance is discussed
in e.g. Kildegaard et al. (2009). Insulin pens have shown
to have a CV of approximately 2%, when giving a dose
of 5U. At large doses, the CV is close to or less than
1%. Heise et al. (2014) studied the impact of volume and
speed of subcutaneous injections on perceived pain. They
found that backflow after injection was less than 1% CV.
Combined with the dosing accuracy of insulin pens, this
amount of variance is not likely to be clinically relevant.
3. SIMULATING A COHORT OF T2D PATIENTS
We use the Medtronic Virtual Patient (MVP) model de-
veloped by Kanderian et al. (2009) and a meal subsystem
described by Hovorka et al. (2004) to simulate a population
of virtual T1D patients, and augment this model with an
endogenous insulin production compartment to simulate
T2D (Ruan et al., 2015). We introduce a method for
simulating injections of long-acting insulin in a simulation
model intended for pump simulations. The ambition of this
model is to represent FG levels in T2D long-acting insulin
treatment.
3.1 Type 1 diabetes model
We use two meal compartments, D1 [mmol] and D2
[mmol], equivalent to what is described by Hovorka et al.
(2004), to describe orally ingested carbohydrates,
dD1(t)
dt
= D(t)− D1(t)
τm
, (1a)
dD2(t)
dt
=
D1(t)
τm
− D2(t)
τm
. (1b)
τm [min] is the peak time of absorption. D(t) [mmol/min]
is the amount of ingested carbohydrates per minute.
Given the amount of orally ingested carbohydrates d(t)
[mg/min], D(t) = AG
d(t)
MwG where MwG = 180.1559
[g/mol] is molar weight of glucose and AG is the unit
less CHO bioavailability. We assume 100% bioavailability,
AG = 1.
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The MVP model is derived from the Bergman minimal
model (Bergman et al., 1981). The model consists of four
compartments, as described in Kanderian et al. (2009).
The insulin absorption subsystem is described by two
compartments, ISC [mU/mL] and IP [mU/mL],
dIsc(t)
dt
=
1
τ1
U(t)
CI
− 1
τ1
Isc(t), (2a)
dIp(t)
dt
=
1
τ2
Isc(t)− 1
τ2
Ip(t), (2b)
where U(t) [mU/min] is the amount of infused fast acting
insulin per minute, CI [mL/min] is the insulin clearance
rate and τ1 and τ2 [min] are time constants of insulin flow
from injection site to plasma and from plasma and out.
Insulin effect on glucose, IEFF [1/min], and blood glucose
concentration, G [mmol/L], are described by
dIeff (t)
dt
= p2SIIp(t)− p2Ieff (t), (3a)
dG(t)
dt
= −(GEZI + Ieff (t))G(t) + EGP +RA, (3b)
where p2 [1/min] is the delay in insulin action after increase
in plasma insulin. SI [mL/mU/min] represents insulin
sensitivity. GEZI [1/min] counts for the effect of glucose
to lower endogenous glucose production at zero insulin.
EGP [mmol/L/min] is the endogenous glucose production
rate. VG [L] is the glucose distribution volume. Rate of
appearance of ingested glucose in plasma is RA =
D2(t)
VGτm
[mmol/L/min].
3.2 Type 2 diabetes augmentation
Ruan et al. (2015) developed six models to describe en-
dogenous plasma insulin concentration based on plasma
glucose concentration. We use the base model which as-
sumes constant parameters throughout the day,
IENDO(t) =
MI(G(t)−Gb) +M0Gb
MCRIW
(4)
IENDO [mU/L] is the endogenous plasma insulin con-
centration. IS(t) [mU/min] is the posthepatic insulin se-
cretion rate. MCRI [L/kg/min] is the insulin metabolic
clearance rate. W [kg] is the subject’s body weight. G
[mmol/L] is the plasma glucose concentration and Gb
[mmol/L] is the fasting plasma glucose concentration. MI
[mU/min/(mmol/L)] is the posthepatic glucose sensitivity
and M0 [mU/min/(mmol/L)] is the basal glucose sensitiv-
ity.
This base model assumes a linear relationship between the
rate of posthepatic insulin secretion and plasma concen-
tration. The endogenous insulin is added to the insulin in
plasma, to affect glucose concentration, so (3a) becomes
dIeff (t)
dt
= p2SI(Ip(t) + IENDO(t))− p2Ieff (t). (5)
To simulate a cohort of 270 patients, we adjust insulin
sensitivity and body weight of the first nine patients iden-
tified in the MVP model (Kanderian et al., 2009) and
choose from the identified parameters of the T2D aug-
mentation (Ruan et al., 2015). The parameter adjustments
and choices are listed in Table 1. We use the maximum
of average GIR profiles of insulin degludec in T1D and
T2D to adjust insulin sensitivity, SI in the MVP model to
Table 1. Choice of parameter adjustments of
the MVP model as defined in Kanderian et al.
(2009) and chosen parameter values of the T2D
augmentation from Ruan et al. (2015).
Parameter Value/Adjustment
SI,T2D [mL/mU] [0.3, 0.4, 0.5, 0.6, 0.7]× SI
WT2D [kg] [1.1, 1.2, 1.3, 1.4, 1.5, 1.6]×W
MCRI [L/kg/min] 0.013
Gb [mmol/L] 7.0
MI [mU/min/(mmol/L)] 0.0
M0 [mU/min/(mmol/L)] 0.7
represent T2D patients. From results by Haahr and Heise
(2014), three hours after injection the maximum GIR of
T2D patients is approximately 50% of the maximum GIR
of the T1D patients. We choose to adjust insulin sensitivity
by 30% to 70%, see Table 1. Similarly we adjust weight
based on average BMI values of the patients randomized
in the two studies discussed in (Haahr and Heise, 2014),
and by assuming equal height of participants. Table 1
presents the body weight adjustments. Distribution vol-
ume of glucose is determined by a linear least squares fit,
VG = aW + b, using the parameters in Kanderian et al.
(2009).
Ruan et al. (2015) present the parameters of complex
endogenous augmentation models where parameters are
assumed to change during the day. Since here the purpose
of the simulation model is to use it in simulating basal
insulin titration, which is based on FG measurement,
we use the parameters corresponding to the night. The
parameters are presented in the bottom three lines of Table
1.
3.3 Long-acting insulin injection
The parameters of the MVP model are fitted to simulate
fast acting insulin for simulation of pump infusion. In order
to simulate a long-acting insulin injection, we used the PK
profile of degludec described by Heise et al. (2012) to define
an infusion profile. Degludec has stable PK exposure and
glucose-lowering effect over 24 hours, and is detectable in
the serum for at least 120 h post-dosing. We simulate the
insulin action profile of an injection, U , as follows,
u(t) = u0 if t ≤ t0, (6a)
u(t) = u0e
(t0−t)/τ if t > t0, (6b)
where t0 is 12 hours, τ is 35 hours and u0 = U/(t0 − t)W .
4. RESULTS
4.1 Comparison with clinical trial data
We simulate a titration period of 26 weeks, where basal
insulin dose is adjusted corresponding to the algorithm
presented in Table 2. This setup is similar to a clinical
trial of insulin degludec in T2D (Zinman et al., 2012). We
add variance to the simulated FG by setting
FˆGt = FGt + vt, (7)
where FˆGt and FGt are simulation with and without bio-
logical noise vt, respectively. In the simulations we assume
a best case scenario where no insulin is omitted and biolog-
ical variance is at minimum. We set vt ∼ N(0, (0.14FGt)2)
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Table 2. The titration algorithm used in a
titration study by Zinman et al. (2012). Dose
adjustments are based on average FG of three
days above target, or the lowest below target.
FG [mmol/L] Dose adjustment
< 3.1 -4U
3.1− 3.9 -2U
4.0− 5.0 In target: no change
5.1− 7.0 +2U
7.1− 8.0 +4U
8.1− 9.0 +6U
> 9.0 +8U
since the standard deviation in untreated T2D discussed
in Section 2 is 14%. Fig 3 illustrates a comparison of FG
levels and the clinical trial results. Considering the two
solid lines, the clinical trial results and simulation results
assuming 100% adherence, both fall within one standard
deviation of the other. Furthermore, the dynamics of aver-
age FG of the cohort are similar. The results indicate that
the simulation results can be used to represent changes in
FG over a titration period in a clinical trial with similar
starting values, patient characteristics and dose guidance.
4.2 Effect of adherence on variability and safety
To evaluate the effect of adherence on variations in FG and
safety of dose guidance, we simulate a similar titration
period as before but with different levels of adherence.
From Fig. 2, adherence is reported to be between 60% and
90%. We choose to simulate three adherence levels, 50%,
70% and 100%, to represent three levels of adherence. Fig.
3 illustrates the FG values in the three adherence scenarios
compared with the clinical data. To evaluate safety of dose
guidance in the different scenarios, we measure:
- Number of FG measurements under 4 mmol/L (FG <
4) and 2.7 mmol/L (FG < 2.7).
- Glycemic coefficient of variation (FG CV).
- Number of times where recommended dose, Ur, is
greater than a dose that would have brought FG
under 4 mmol/L, (Ur > U4), and 2.7 mmol/L, (Ur >
U2.7).
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Fig. 3. Results from a clinical trial (Zinman et al., 2012)
and simulations of 270 T2D patients. The results
represent the same drug, the same titration algorithm,
and similar inclusion criteria.
Table 3. Results from a simulated titration
period of 26 weeks for adherence levels 50%,
70% and 100% (mean (standard deviation)).
Adherence
Measure 50% 70% 100%
FG < 4 [%] 7.7 (7.7) 6.8 (7.1) 4.9 (4.3)
FG < 2.7 [%] 0.4 (0.9) 0.1 (0.4) 0.0
FG CV [%] 30.1 (5.6) 28.1 (3.7) 21.6 (2.1)
Ur > U4 [%] 24.4 (27.5) 5.3 (13.8) 0.0
Ur > U2.7 [%] 0.2 (1.1) 0.0 0.0
The results are presented in Table 3 as the percentage
of days out of 26 weeks where the events listed above
occur. The results indicate a difference in FG variance
of the 270 patients in the three adherence scenarios.
Coefficient of variation is 21.6%(2.1%) where no doses were
omitted, 28.1%(3.7%) for 70% adherence and 30.1(5.6)
for 50% adherence. Similarly, the results indicate that
the number of times where a recommended dose Ur was
larger than a dose that would lower FG below target, U4.
This never occurred in the perfect adherence case, but
5.3%(13.8%) and 24.4%(27.5%) of recommended doses for
70% and 50% adherence, respectively. However, there does
not seem to be a difference in number of hypoglycemic
events. A possible explanation could be when a too large
dose is recommended but not injected, it will not cause
hypoglycemia.
In the simulations of different adherence levels, we find
that FG has a coefficient of variation between 20% and
30% on average. This is lower than the 35% mentioned in
Section 2. It must be pointed out that this simulation only
assumes 14% biological variance in FG and does not take
PK/PD variance into account.
5. CONCLUSIONS
This paper presents a review of sources of variance in long-
acting insulin treatment for T2D patients and suggests
a categorization. Biological variance caused by PK/PD
of insulin varies greatly between types of basal insulin.
Accuracy of devices is a minor factor compared with other
variance sources including biological variance and adher-
ence to treatment. It should be noted that the group of
T2D patients more heterogeneous than T1D. Categorizing
sources of variability in T2D is not necessarily as simple as
for T1D, as it may be different depending on the severity
of the disease.
We suggest a model of glucose-insulin dynamics to gener-
ate a cohort of T2D patients initiating long-acting insulin
treatment. The results indicate that the model is sufficient
to simulate FG levels of T2D patients in-silico during a
long-acting insulin titration period. Results from compar-
ing dose suggestions and FG levels in different adherence
scenarios indicate that dose guidance algorithms should
take adherence into account to ensure safe dose guidance.
We should furthermore mention that adherence is evi-
dently crucial to reaching recommended goals in insulin
treatment. We have shown that adherence is essential to
safe treatment when using dose guidance algorithms.
The motivation for creating this model was to simulate
FG values in T2D during a titration period. For the
purpose of bolus calculations and more detailed meal
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titration study by Zinman et al. (2012). Dose
adjustments are based on average FG of three
days above target, or the lowest below target.
FG [mmol/L] Dose adjustment
< 3.1 -4U
3.1− 3.9 -2U
4.0− 5.0 In target: no change
5.1− 7.0 +2U
7.1− 8.0 +4U
8.1− 9.0 +6U
> 9.0 +8U
since the standard deviation in untreated T2D discussed
in Section 2 is 14%. Fig 3 illustrates a comparison of FG
levels and the clinical trial results. Considering the two
solid lines, the clinical trial results and simulation results
assuming 100% adherence, both fall within one standard
deviation of the other. Furthermore, the dynamics of aver-
age FG of the cohort are similar. The results indicate that
the simulation results can be used to represent changes in
FG over a titration period in a clinical trial with similar
starting values, patient characteristics and dose guidance.
4.2 Effect of adherence on variability and safety
To evaluate the effect of adherence on variations in FG and
safety of dose guidance, we simulate a similar titration
period as before but with different levels of adherence.
From Fig. 2, adherence is reported to be between 60% and
90%. We choose to simulate three adherence levels, 50%,
70% and 100%, to represent three levels of adherence. Fig.
3 illustrates the FG values in the three adherence scenarios
compared with the clinical data. To evaluate safety of dose
guidance in the different scenarios, we measure:
- Number of FG measurements under 4 mmol/L (FG <
4) and 2.7 mmol/L (FG < 2.7).
- Glycemic coefficient of variation (FG CV).
- Number of times where recommended dose, Ur, is
greater than a dose that would have brought FG
under 4 mmol/L, (Ur > U4), and 2.7 mmol/L, (Ur >
U2.7).
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Fig. 3. Results from a clinical trial (Zinman et al., 2012)
and simulations of 270 T2D patients. The results
represent the same drug, the same titration algorithm,
and similar inclusion criteria.
Table 3. Results from a simulated titration
period of 26 weeks for adherence levels 50%,
70% and 100% (mean (standard deviation)).
Adherence
Measure 50% 70% 100%
FG < 4 [%] 7.7 (7.7) 6.8 (7.1) 4.9 (4.3)
FG < 2.7 [%] 0.4 (0.9) 0.1 (0.4) 0.0
FG CV [%] 30.1 (5.6) 28.1 (3.7) 21.6 (2.1)
Ur > U4 [%] 24.4 (27.5) 5.3 (13.8) 0.0
Ur > U2.7 [%] 0.2 (1.1) 0.0 0.0
The results are presented in Table 3 as the percentage
of days out of 26 weeks where the events listed above
occur. The results indicate a difference in FG variance
of the 270 patients in the three adherence scenarios.
Coefficient of variation is 21.6%(2.1%) where no doses were
omitted, 28.1%(3.7%) for 70% adherence and 30.1(5.6)
for 50% adherence. Similarly, the results indicate that
the number of times where a recommended dose Ur was
larger than a dose that would lower FG below target, U4.
This never occurred in the perfect adherence case, but
5.3%(13.8%) and 24.4%(27.5%) of recommended doses for
70% and 50% adherence, respectively. However, there does
not seem to be a difference in number of hypoglycemic
events. A possible explanation could be when a too large
dose is recommended but not injected, it will not cause
hypoglycemia.
In the simulations of different adherence levels, we find
that FG has a coefficient of variation between 20% and
30% on average. This is lower than the 35% mentioned in
Section 2. It must be pointed out that this simulation only
assumes 14% biological variance in FG and does not take
PK/PD variance into account.
5. CONCLUSIONS
This paper presents a review of sources of variance in long-
acting insulin treatment for T2D patients and suggests
a categorization. Biological variance caused by PK/PD
of insulin varies greatly between types of basal insulin.
Accuracy of devices is a minor factor compared with other
variance sources including biological variance and adher-
ence to treatment. It should be noted that the group of
T2D patients more heterogeneous than T1D. Categorizing
sources of variability in T2D is not necessarily as simple as
for T1D, as it may be different depending on the severity
of the disease.
We suggest a model of glucose-insulin dynamics to gener-
ate a cohort of T2D patients initiating long-acting insulin
treatment. The results indicate that the model is sufficient
to simulate FG levels of T2D patients in-silico during a
long-acting insulin titration period. Results from compar-
ing dose suggestions and FG levels in different adherence
scenarios indicate that dose guidance algorithms should
take adherence into account to ensure safe dose guidance.
We should furthermore mention that adherence is evi-
dently crucial to reaching recommended goals in insulin
treatment. We have shown that adherence is essential to
safe treatment when using dose guidance algorithms.
The motivation for creating this model was to simulate
FG values in T2D during a titration period. For the
purpose of bolus calculations and more detailed meal
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simulations, the model parameters related to carbohydrate
uptake should be refined. Also the choice of endogenous
insulin production model should be improved to allow
daily fluctuations.
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